Madrigal Pharmaceuticals ( (MDGL) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Madrigal Pharmaceuticals’ stock has surged due to strong Q3 2025 growth and promising trial data for its drug, Rezdiffra, which showed significant improvements in liver conditions. This positive sentiment has led analysts to raise their price targets, despite the company reporting a GAAP net loss. The strategic positioning and successful drug trials have further boosted analyst ratings.
More about Madrigal Pharmaceuticals
YTD Price Performance: 58.03%
Average Trading Volume: 366,130
Technical Sentiment Signal: Buy
Current Market Cap: $11.11B
For further insights into MDGL stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.